



Conference: Nordic HPB - NOLCA, HELSINKI

18 – 19 September 2025

Hotel Hilton Kalastajatorppa

Thursday 18 September

08.30 Registration

09.00 Welcome by tbc

09.10 – 10.30 Session I: HPB – Robotics / Mini-invasive

There's enough evidence to justify robotic Whipple, tha 15 mins

There's not enough evidence to justify robotic Whipple, tha 15 mins

Open versus laparoscopic versus robotic liver surger – New thoughts from ROC'n'ROLL / ROBOCOP trials? *tba* 15min

Should we ablate them all? – How to apporach colorectal liver metastases after COLLISION / New COMET, *tba* 15min

1 free slot / DISCUSSION - 20min

10.30 - 10.50 Coffee/Exhibition

10.50 – 12.30 Session II: EUS / advanced endoscopic techniques

Changing role of EUS in work up of IPMN? tha 15 min

In seek for tissue in pancreatic cancer and cholangiocarcinoma— Tandem lecture: Oncologist&Endoscopist 20min

Why novel oncological therapies require tissue instead of cytology? – *Oncologist tha* 10min

How to get enough tissue? Endoscopist tha 10 min





Nordic HPB

Management of HPB surgery complications using EUS and ERCP – *tba* min

Palliative endoscopic / EUS techniques – Lessons from a low-volume center – *tha* 15 min

Surgery for all now? How to interpret latest evidence on chronic pancreatitis (ESCAPE trial)? -tba 15min

1 free slot / DISCUSSION 20 min

12.30 – 13.30 Lunch/Exhibition

13.30 – 15:00 Session III: Maximally invasive HPB

When oncologists makes surgery happen: Downstaging in pancreatic cancer and cholangiocarcinoma, *tba* 15min

Venous resections – When and what to use as a graft? What to do with splenic vein? How to deal with early / late thrombosis/stenosis? *tba*, 15min

New frontiers in transplant oncology: Intrahepatic cholangiocarcinoma, *Pål-Dag Line*, Oslo, 15min

When multivisceral resections are needed? tha 15min

2 free slots / DISCUSSION 30 mins

15.00 – 15.30 Poster presentations - Physical presence of the presenter mandatory at this time!

15.30 - 15.50 Coffee/Exhibition

15.50 - 16:40 Free papers

6-8 mins per presentation = 5-7 presentations.

16.40 - 17.00 Most important HPB papers 2025 - tba





Nordic HPB

17.00 – 17.30 New / ongoing / breaking results - trial / study session 1

Nordic Pancreatic Cancer Network info – Roland Andersson, Lund 10min

2 free slots á 10min

17:30 – 17:40 Presidential address

17.40 – 18.00 General Assembly

19.15 Conference Dinner





Friday 19 September

NOLCA

	NOLCA
08.30 - 08.35	Welcome by Pia Österlund, Helsinki
	HCC Real-world evidence" in the Nordics. Chair: Peter Jepsen
08.35 – 08.45	Introduction to the session including results of the PERLA study (prognosis of HCC treated with resection or ablation), <i>Peter Jepsen</i> , Aarhus
08.45 - 08.55	Treatment patterns and outcomes of patients with HCC in Denmark, Hans-Christian Pommergaard, Copenhagen
08.55 - 09.05	Treatment patterns and outcomes of patients with HCC in Finland, <i>Pia Österlund</i> , Helsinki
09.05 – 09.15	Treatment patterns and outcomes of patients with HCC in Sweden (OPAL study), <i>Hannes Hagström</i> , Stockholm
09.15 – 09.40	Roundtable: Peter Jepsen hosting, presenters seated on-stage, audience participating.
	What is the role of RWE studies? Why are these studies done <u>separately</u> for each country and not as Nordic collaborations? Discuss challenges.
09.40 - 10.05	Coffee/exhibition
10.05 - 10.20	Macrovascular invasion of HCC: What is it, and how does it affect locoregional and systemic treatments? <i>Malin Sternby Eilard</i> , Göteborg and <i>Per Stål</i> , Stockholm
10.20 - 10.45	Sequential treatments for HCC: SIRT \rightarrow ICI \rightarrow resection? Including a suggestion for a Nordic protocol, $Bård$ $Røsok$, Oslo and tba
10.45 - 11.10	Invited star lecture on cholangiocarcinoma, tha
11.10 - 11.20	Young presenter #1, Abstract competition





Young presenter #2, Abstract competition

- 11.30 11.45 General Assembly NOLCA, Pia Österlund, Helsinki
- 11.45 12.45 Lunch and exhibition
- 12.45 13.15 New study / trial session 2
- Early diagnosis of hereditary pancreatic cancer (SHIELD study) *Anna Brodén*, Lund 10 min
- Prediction of pancreatic fistula after pancreatoduodenectomy *Tiia Ojala/ Akseli Bonsdorff*, Helsinki 10 min
- 1 slot available á 10 min

11.20 - 11.30

13.15 – 14.45 **Session IV**: HPB complications

How to assess risk of posthepatectomy liver failure preoperatively and where to set the treshold for resection? *TBA* 15min

Reducing risks of bleeding & tromboembolic complications in HPB – What new does POISE3, HELIX, PRICE-2, and PREPOSTEROUS bring to the table? *Ville Sallinen*, Helsinki 15min

Bilobar colorectal liver metastasis – What is the optimal strategy? Double vein embolization, ALPPS, portal vein embolization, or two-stage hepatectomy? *TBA* 15min

Arterial resections in pancreatic surgery – When is the right time? How to deal with early/late thrombosis/stenosis/bleeding? *TBA* 20 min

Discussion 10 min

14.45 Prizes for best oral & poster abstract presentation

14.55 - 15.00 Summing up, Roland Andersson and Ville Sallinen





Nurses' program

Friday 19 September

08.30 - 09.00	Registration
09.00 - 09.05	Welcome, Xxxx Xxx, Helsinki
09.05 - 09.40	Nurses program tba
09.40 - 10.05	Coffee Break
10.05 - 11.45	Nurses program tba
11.45 - 12.45	Lunch